Impact of antiplatelet effect of monotherapy with clopidogrel on clinical events in patients on vitamin K-antatonists undergoing coronary stent implantatio

• Conditions: I25; Chronic ischaemic heart disease

• Registration Number: DRKS00007144
• Lead Sponsor: niversitäts-Herzzentrum Freiburg Bad KrozingenKlinik für Kardiologie und Angiologie II

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-11-10
• Study Completion: 2015-11-27
• Results First Posted: 2018-09-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

patients undergoing coronary stent implantation with indication for oral anticoagulation for at least 6 months
- pretreatment with ASA and clopidogrel
- planned treatment with clopidogrel and vitamin K-antagonist following percutaneous coronary intervention
- age >=18 years
- written informed consent

Exclusion Criteria

- high-risk acute coronary syndrome (because usually treated with triple therapy)
- fibrinolysis or GP IIb/IIIa antagonist with 5 days before enrollment
- contraindication for clopidogrel or vitamin K-antagonist
-thrombopenia
- known severe coagulopathy
- severe disease leading to a life expectancy of less than 1 year

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
death or non-fatal myocardial infarction within 6 months following coronary stent implantation

Secondary Outcome Measures

Name	Time	Method
prevalence of high on-treatment platelet reactivity<br>further ischemic endpoints such as urgent revascularization